Advertisement

Picture Kentro Design Is Key to Your Success Berlin 650x100px
Organisation › Details

LimmaTech Biologics AG

LimmaTech Biologics AG was incorporated following the acquisition of GlycoVaxyn by GSK in February 2015 and is a clinical-stage biopharmaceutical company, developing recombinant vaccines for major infectious diseases using a technology previously developed by GlycoVaxyn and now owned by GSK. The company is primarily dedicated to applying this technology to the development of bioconjugate vaccines and will also generate proprietary therapeutic products in areas outside of vaccines. *

 

Period Start 2015-05-21 established
  Predecessor GlycoVaxyn AG
Products Industry vaccine technology
  Industry 2 vaccine
Persons Person Haas, Franz-Werner (LimmaTech Biologics 202307– CEO before CureVac + Sygnis Pharma + Lion BIoscience + Sirona Dental)
  Person 2 Dro, Philippe (LimmaTech Biologics 202307 Board Chair before CEO + Co-Founder before GlycoVaxyn CEO)
     
Region Region Schlieren ZH
  Country Switzerland
  Street 3 Grabenstr.
  City 8952 Schlieren ZH
  Tel +41-44-733-8585
    Address record changed: 2023-09-04
     
Basic data Employees n. a.
     
    * Document for »About Section«: 
     
   
Record changed: 2023-12-20

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for LimmaTech Biologics AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x300px




» top